Product image of Oedien (Dienogest, Ethinylestradiol | Lactose) supplied by GNH India

Oedien

Active Ingredient:
Dienogest, Ethinylestradiol | Lactose
Origin:
EU

Oedien (Dienogest, Ethinylestradiol | Lactose)

Dienogest, the active ingredient in Oedien, is a progestogenic component of a combined oral contraceptive presented as tablets for oral use. It is paired with ethinyloestradiol to provide hormonal contraception and to manage endometriosis‑related symptoms in women of reproductive age.

GNH India supplies Oedien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratoires Bailleul S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Oedien, a combined oral contraceptive, is employed in hormonal regulation and reproductive health management.

  • Contraception: prevention of pregnancy in women of reproductive age.
  • Endometriosis management: reduction of pelvic pain and lesion progression.
  • Menstrual cycle regulation: improvement of cycle regularity and reduction of heavy bleeding.

How It Works

  • Dienogest acts as a selective progestogen, while ethinyloestradiol provides estrogenic activity. Together they suppress the hypothalamic‑pituitary‑ovarian axis, inhibiting the mid‑cycle luteinising hormone surge and preventing ovulation. The progestogen also induces cervical mucus thickening and endometrial transformation, creating an environment hostile to sperm and implantation.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Breast tenderness: temporary swelling or discomfort.
  • Headache: occasional mild to moderate pain.
  • Weight gain: slight increase in body weight.
  • Mood changes: fluctuations in emotional state.
  • Breakthrough bleeding: irregular spotting between periods.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins.
  • Arterial thrombosis: clot formation in arteries, potentially causing stroke.
  • Hypertension: elevated blood pressure.
  • Liver disorders: jaundice or hepatic dysfunction.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Visual disturbances: sudden vision changes or loss.

Precautions & Warnings

Before initiating Oedien, consider the following safety measures.

  • Contraindications: known thrombosis, estrogen‑dependent tumor, pregnancy, severe liver disease.
  • Smoking: avoid use in women over 35 who smoke.
  • Cardiovascular risk: assess history of hypertension, stroke, or myocardial infarction.
  • Drug interactions: review concomitant medications that may affect efficacy.
  • Monitoring: periodic blood pressure and lipid profile checks recommended.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Oedien may interact with several medicines; awareness of interaction severity is essential.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive effectiveness.
  • Anticoagulants (e.g., warfarin): increased risk of thrombotic events.
  • Hepatotoxic drugs (e.g., certain antitubercular agents): heightened liver strain.

Moderate Interactions (Monitor Closely)

  • SSRIs (e.g., fluoxetine): may increase bleeding tendency.
  • Anticonvulsants (e.g., phenytoin): moderate reduction in hormone levels.
  • Herbal supplements (e.g., St. John’s wort): potential decrease in contraceptive efficacy.
  • Antifungals (e.g., ketoconazole): may increase hormone concentrations.
  • Antibiotics (e.g., clarithromycin): possible modest effect on hormone metabolism.

Frequently Asked Questions

Oedien is a combined oral contraceptive containing Dienogest and Ethinylestradiol. It is prescribed to prevent pregnancy, to manage symptoms of endometriosis, and to regulate menstrual cycles in women of reproductive age.

Dienogest is a progestogen that, together with the estrogen component Ethinylestradiol, suppresses the hypothalamic‑pituitary‑ovarian axis. This inhibition prevents the mid‑cycle luteinising hormone surge, thereby blocking ovulation and creating cervical mucus and endometrial changes that reduce the chance of fertilisation and implantation.

The specific dosage regimen for Oedien is determined by the prescribing healthcare professional based on individual patient factors. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Oedien is contraindicated during pregnancy because it is intended to prevent conception. Women who become pregnant should discontinue use immediately. Limited data exist for breastfeeding; however, combined hormonal contraceptives are generally considered compatible with lactation, though a clinician should evaluate risks and benefits.

To request Oedien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oedien combines Dienogest, a progestogen with a favorable profile for endometriosis symptom control, and Ethinylestradiol, a standard estrogen component. Compared with other COCs that use different progestins, Oedien may offer improved relief of endometriosis‑related pain while maintaining comparable contraceptive efficacy.

Oedien tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Oedien is taken orally, typically as one tablet daily at the same time each day. The regimen usually follows a 21‑day active tablet sequence followed by a hormone‑free interval, but patients must follow the specific schedule prescribed by their healthcare provider.

The most serious risks include venous thromboembolism, arterial thrombosis, hypertension, and severe liver disorders. Patients with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should be evaluated carefully before using Oedien.

Oedien should not be used by women who are pregnant, have known thromboembolic disease, estrogen‑dependent tumors, uncontrolled hypertension, severe liver disease, or who are over 35 and smoke heavily. Contraindications must be confirmed by a qualified healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Dienogest, Ethinylestradiol | Lactose

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT